What does this research mean for the field?

While long-term all-cause mortality is generally comparable between ViV-TAVR and redo-SAVR, ViV-TAVR offers lower perioperative risks for high-risk patients, whereas redo-SAVR provides superior long-term durability and lower risk of patient-prosthesis mismatch for younger, lower-risk patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 24, 2026Journal of Cardiothoracic SurgeryOpen Access

Comparing short- and long-term outcomes of transcatheter valve-in-valve versus redo surgical aortic valve replacement: a literature review

Q: What is the clinical evidence from this study?

Study design: Review. Population: Degenerated bioprosthetic aortic valves. Intervention: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) vs. Redo-surgical aortic valve replacement (redo-SAVR). Primary outcome: All-cause mortality.

View Full Paper

Ask AI

Bookmark

Key result

ViV-TAVR yields comparable long-term mortality to redo-SAVR for degenerated bioprosthetic aortic valves.

Why the study?

ViV-TAVR and redo-SAVR are key strategies for degenerated bioprosthetic aortic valves, but tradeoffs remain regarding durability, procedural risks, gradients, and long-term outcomes.

Does ViV-TAVR compared to redo-SAVR improve outcomes in patients with degenerated bioprosthetic aortic valves?

Population

Patients with degenerated bioprosthetic aortic valves

Comparison

ViV-TAVR vs redo-SAVR

Design

Literature review of propensity-score matched studies and meta-analyses

Authors

PEPouya Ebrahimi REReza Eshraghi AMAli Moradi

Discussion

Member takes

Overview

May support individualized decisions; leaves open need for randomized trials on durability and rehospitalization.

Key Points

This review aims to compare the short- and long-term outcomes of valve-in-valve transcatheter aortic valve replacement and redo surgical aortic valve replacement in managing degenerated bioprosthetic valves.
Analyzed outcomes from propensity-score matched studies and meta-analyses comparing ViV-TAVR and redo-SAVR.
Evaluated perioperative risks, long-term durability, and rates of complications such as myocardial infarction and patient-prosthesis mismatch.
Long-term all-cause mortality rates were generally similar between ViV-TAVR and redo-SAVR, though some studies suggest an advantage for redo-SAVR in selected groups.
ViV-TAVR associated with increased hospitalizations for heart failure after two years; redo-SAVR linked to lower rates of myocardial infarction and improved short-term outcomes.
ViV-TAVR showed a lower risk of atrial fibrillation and major adverse cardiovascular events compared to redo-SAVR.

Structured PICO

Does ViV-TAVR compared to redo-SAVR improve outcomes in patients with degenerated bioprosthetic aortic valves?

Population

Patients with degenerated bioprosthetic aortic valves

Intervention

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR)

Comparator

Redo surgical aortic valve replacement (redo-SAVR)

Outcome

Long-term all-cause mortalityhard clinical

ViV-TAVR and redo-SAVR offer comparable long-term mortality for degenerated bioprosthetic aortic valves, but ViV-TAVR has lower perioperative risks while redo-SAVR provides better longevity and lower risk of patient-prosthesis mismatch.

Limitations

Heterogeneous results across included studies
Ongoing concerns regarding long-term durability, higher transvalvular gradients, and potential coronary obstruction with ViV-TAVR

Cite This Study

Ebrahimi et al. (2026) conducted a review in Degenerated bioprosthetic aortic valves. Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) vs. Redo-surgical aortic valve replacement (redo-SAVR) was evaluated on All-cause mortality. Valve-in-valve transcatheter aortic valve replacement and redo-surgical aortic valve replacement demonstrated generally comparable long-term all-cause mortality for managing degenerated bioprosthetic aortic valves.

synapsesocial.com/papers/6a12964948a0ea1665672f50 https://doi.org/10.1186/s13019-026-04105-w

View Full Paper

Ask AI

Bookmark

May 24, 2026Journal of Cardiothoracic SurgeryOpen Access

Comparing short- and long-term outcomes of transcatheter valve-in-valve versus redo surgical aortic valve replacement: a literature review

View Full Paper

Ask AI

Bookmark

Key result

ViV-TAVR yields comparable long-term mortality to redo-SAVR for degenerated bioprosthetic aortic valves.

Why the study?

ViV-TAVR and redo-SAVR are key strategies for degenerated bioprosthetic aortic valves, but tradeoffs remain regarding durability, procedural risks, gradients, and long-term outcomes.

Does ViV-TAVR compared to redo-SAVR improve outcomes in patients with degenerated bioprosthetic aortic valves?

Population

Patients with degenerated bioprosthetic aortic valves

Comparison

ViV-TAVR vs redo-SAVR

Design

Literature review of propensity-score matched studies and meta-analyses

Authors

PEPouya Ebrahimi REReza Eshraghi AMAli Moradi

Discussion

Member takes

Overview

May support individualized decisions; leaves open need for randomized trials on durability and rehospitalization.

Key Points

This review aims to compare the short- and long-term outcomes of valve-in-valve transcatheter aortic valve replacement and redo surgical aortic valve replacement in managing degenerated bioprosthetic valves.
Analyzed outcomes from propensity-score matched studies and meta-analyses comparing ViV-TAVR and redo-SAVR.
Evaluated perioperative risks, long-term durability, and rates of complications such as myocardial infarction and patient-prosthesis mismatch.
Long-term all-cause mortality rates were generally similar between ViV-TAVR and redo-SAVR, though some studies suggest an advantage for redo-SAVR in selected groups.
ViV-TAVR associated with increased hospitalizations for heart failure after two years; redo-SAVR linked to lower rates of myocardial infarction and improved short-term outcomes.
ViV-TAVR showed a lower risk of atrial fibrillation and major adverse cardiovascular events compared to redo-SAVR.

Structured PICO

Does ViV-TAVR compared to redo-SAVR improve outcomes in patients with degenerated bioprosthetic aortic valves?

Population

Patients with degenerated bioprosthetic aortic valves

Intervention

Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR)

Comparator

Redo surgical aortic valve replacement (redo-SAVR)

Outcome

Long-term all-cause mortalityhard clinical

Limitations

Heterogeneous results across included studies
Ongoing concerns regarding long-term durability, higher transvalvular gradients, and potential coronary obstruction with ViV-TAVR

Cite This Study

synapsesocial.com/papers/6a12964948a0ea1665672f50 https://doi.org/10.1186/s13019-026-04105-w

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark